Physician profile
Rahul Mandiga
NPI 1083800502
$16,710.52
in general payments reported to CMS, 2019-2025
23 companies · $10K in 2025
The $10K reported for 2025 was more than what 91% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $96.41 · 2021: $419 · 2022: $357 · 2023: $2,132 · 2024: $2,961 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $2,370 · Travel and Lodging: $1,125 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,059.50 |
| Food and Beverage | $2,370.16 |
| Travel and Lodging | $1,124.93 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $10,755.76 | 2022-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $2,226.23 | 2022-2025 | Syfovre |
| Abbvie INC. | $1,141.39 | 2022-2025 | |
| Harrow Eye, LLC | $729.15 | 2025 | Triesence, Iheezo |
| Regeneron Healthcare Solutions, INC. | $454.17 | 2019-2025 | Eylea Hd, Eylea |
| Notal Vision, INC. | $400.22 | 2021-2025 | Foresee Home |
| Novartis Pharmaceuticals Corporation | $149.34 | 2019 | |
| Alimera Sciences, INC. | $142.47 | 2019-2024 | Iluvien, Yutiq |
| Johnson & Johnson Surgical Vision, INC. | $124.79 | 2024 | Tecnis Iol, Catalys System |
| Alcon Vision LLC | $111.61 | 2024 | Constellation, Clareon |
| Ani Pharmaceuticals, INC. | $88.70 | 2025 | Iluvien, Purified Cortrophin Gel |
| Genentech, INC. | $72.52 | 2024-2025 | Vabysmo |
| Astellas Pharma US INC | $46.02 | 2024-2025 | Izervay |
| Glaukos Corporation | $43.12 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Carl Zeiss Meditec, INC. | $42.54 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Eyepoint US, INC. | $34.40 | 2021 | |
| Topcon Healthcare, INC. | $28.04 | 2025 | |
| Sun Pharmaceutical Industries INC. | $22.73 | 2019 | |
| Amgen INC. | $17.32 | 2025 | Tepezza |
| Allergan, INC. | $16.21 | 2020 | |
| Spark Therapeutics, INC. | $14.06 | 2019 | |
| Glaxosmithkline, LLC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Mandiga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.